Product Description
The DV4-E88 monoclonal antibody reacts with the DIII domain on the E protein of dengue virus serotype 4 (DENV-4). This serotype-specific antibody does not cross-react with DENV-1, DENV-2, or DENV-3, i.e., the other serotypes of dengue virus (DENV). DENV is an Aedes aegypti and A. albopictus mosquito-transmitted flavivirus that causes over 100 million annual infections in tropical and sub-tropical regions. Mild dengue illness is characterized by fever, headache, and myalgia, while severe dengue disease can lead to hemorrhagic and capillary leak syndrome, i.e., dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS). Structurally, DENV is a single-stranded positive-polarity RNA virus, with its envelop (E) protein having three domains. The DV4-E88 monoclonal antibody binds (conformationally) to the lateral ridge (LR) of Domain III (DIII) on DENV-4 (quaternary epitope on the E dimer). This antibody does not recognize yeast surface expressed or isolated DENV-4 E protein DIII. The DIII-LR region contains host cell surface receptor recognition sites, and it is involved in the induction of virus-neutralizing antibodies. In in vitro studies, the DV4-E88 monoclonal antibody neutralized 1036, TVP-376, and TVP-986 genotype II strains of DENV-4. In experiments involving AG129 mice, a single in vivo injection of DV4-E88 monoclonal antibody (100-500 µg/mouse) prior to viral infection provided modest to significant protection against DENV-4 strains H-241 and TVP-376.
* VAT and shipping costs not included. Errors and price changes excepted
